Journal of Thoracic Oncology (JTO), July 2019, Volume 14, Issue 7
Journal | English | 2019
Image For Activity Cover
Credit Offered
No Credit Offered
  • Immunotherapy for NSCLC With Brain Metastases: What Can We Learn From Real-World Data?
  • Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC
  • Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity
Editorial - Lung Cancer Worldwide
  • Lung Cancer in Canada
Review Articles
  • Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
  • Detecting Pathological Complete Response in Esophageal Cancer after Neoadjuvant Therapy Based on Imaging Techniques: A Diagnostic Systematic Review and Meta-Analysis
Special Article
  • The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation
Original Articles
  • Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer
  • Circulating Inflammation Proteins Associated With Lung Cancer in African Americans
  • Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients
  • The Landscape of Actionable Molecular Alterations in ImmunomarkerDefined Large-Cell Carcinoma of the Lung
  • Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer Staging
  • Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study
  • Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors
  • Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
  • Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
  • Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer
  • Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer
  • 18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial
Case Report
  • Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest. Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic science studies must have direct clinical and translational relevance.

Authors are also welcome to submit to the journal's open access companion title, JTO Clinical and Research Reports, which welcomes a range of manuscripts from subset analyses of published trials to high-quality case reports
Powered By